JP2019529487A5 - - Google Patents

Download PDF

Info

Publication number
JP2019529487A5
JP2019529487A5 JP2019517027A JP2019517027A JP2019529487A5 JP 2019529487 A5 JP2019529487 A5 JP 2019529487A5 JP 2019517027 A JP2019517027 A JP 2019517027A JP 2019517027 A JP2019517027 A JP 2019517027A JP 2019529487 A5 JP2019529487 A5 JP 2019529487A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
cooh
appearance
coor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019517027A
Other languages
English (en)
Japanese (ja)
Other versions
JP7086945B2 (ja
JP2019529487A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/054053 external-priority patent/WO2018064356A1/en
Publication of JP2019529487A publication Critical patent/JP2019529487A/ja
Publication of JP2019529487A5 publication Critical patent/JP2019529487A5/ja
Application granted granted Critical
Publication of JP7086945B2 publication Critical patent/JP7086945B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019517027A 2016-09-29 2017-09-28 狼瘡を処置するための化合物および方法 Active JP7086945B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662401762P 2016-09-29 2016-09-29
US62/401,762 2016-09-29
PCT/US2017/054053 WO2018064356A1 (en) 2016-09-29 2017-09-28 Compounds and methods for treating lupus

Publications (3)

Publication Number Publication Date
JP2019529487A JP2019529487A (ja) 2019-10-17
JP2019529487A5 true JP2019529487A5 (enExample) 2020-09-10
JP7086945B2 JP7086945B2 (ja) 2022-06-20

Family

ID=60043386

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019517027A Active JP7086945B2 (ja) 2016-09-29 2017-09-28 狼瘡を処置するための化合物および方法

Country Status (7)

Country Link
US (1) US11278526B2 (enExample)
EP (1) EP3518922B1 (enExample)
JP (1) JP7086945B2 (enExample)
KR (1) KR102408814B1 (enExample)
CA (1) CA3038106A1 (enExample)
ES (1) ES3068290T3 (enExample)
WO (1) WO2018064356A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3630738T (pt) * 2017-05-22 2023-10-24 Egyt Gyogyszervegyeszeti Gyar Processo para a produção de ozanimod
AR116479A1 (es) 2018-09-25 2021-05-12 Quim Sintetica S A Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios
CN113891883A (zh) * 2019-03-29 2022-01-04 瑞塞普托斯公司 1-磷酸鞘氨醇受体调节剂
CN116332794B (zh) * 2021-12-24 2024-10-15 上海合全药物研发有限公司 一种芳基腈类化合物的制备方法
IL319505A (en) * 2022-09-14 2025-05-01 Viatris Asia Pacific Pte Ltd S1P 1 receptor modulators for use in the treatment of diseases mediated by type 1 interferon
WO2026035999A1 (en) 2024-08-09 2026-02-12 Triana Biomedicines, Inc. Anaplastic lymphoma kinase (alk) degraders and uses thereof
CN122301787A (zh) * 2024-12-31 2026-06-30 南京易腾药物研究院有限公司 一种季铵盐类局部作用的1-磷酸鞘氨醇受体亚型1激动剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080306124A1 (en) 2005-06-08 2008-12-11 Rainer Albert Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands
CN101522646A (zh) 2006-09-29 2009-09-02 诺瓦提斯公司 具有抗炎和免疫抑制特性的二唑衍生物
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
PT2291080E (pt) 2008-05-14 2015-10-30 Scripps Research Inst Novos modelamodeladores dos recetores da esfingosina fosfato
PL2498610T5 (pl) 2009-11-13 2024-11-04 Receptos Llc Selektywne modulatory receptora sfingozyno-1-fosforanu i sposoby syntezy chiralnej
WO2015066515A1 (en) * 2013-11-01 2015-05-07 Receptos, Inc. Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith

Similar Documents

Publication Publication Date Title
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2020507582A5 (enExample)
JP2018514568A5 (enExample)
JP2019034943A5 (enExample)
RU2009148673A (ru) Производные пиразинона и их применение для лечения легочных заболеваний
JP2016536363A5 (enExample)
JP2019500387A5 (enExample)
RU2019120990A (ru) Бициклические гетероарильные производные в качестве стимуляторов cftr
JP2020532578A5 (enExample)
JP2016536364A5 (enExample)
JP2012524111A5 (enExample)
JP2014500265A5 (enExample)
RU2013126947A (ru) Соединения, пригодные для лечения спида
JP2016518434A5 (enExample)
JP2003502405A5 (enExample)
JP2018537535A5 (enExample)
RU2017141561A (ru) Производные тетрагидронафтиридинилпропионовой кислоты и их применение
CA2628844A1 (en) Pyrazole derivatives and their medical use
JP2010527984A5 (enExample)
JP2006501201A5 (enExample)
RU2010142936A (ru) НОВЫЕ ПРОИЗВОДНЫЕ ПИПЕРАЗИНА КАК ИНГИБИТОРЫ СТЕАРОИЛ-КоА ДЕСАТУРАЗЫ
JP2020531593A5 (enExample)
JP2018510202A5 (enExample)
RU2017118369A (ru) Соединения для применения в дегельминтизации
JP2012524110A5 (enExample)